
Gilead Surprises with Strong Q1 Earnings: Beat Estimates Amidst Pharmaceutical Industry Uncertainties
Gilead Sciences Surpasses Wall Street Estimates with Strong Fourth-Quarter Results Gilead Sciences, a leading biopharmaceutical company, reported fourth-quarter financial results that outpaced Wall Street expectations on Tuesday. The company’s total revenue came in at $7.6 billion, a 12% increase year-over-year, while earnings per share reached $2.34, exceeding analysts’ predictions by $0.31. Driving the Growth: HIV…